Table 1.
Patient and tumor characteristics in primary and validation cohorts.
| Response(n = 71) | Nonresponse(n = 56) | P-value | |
|---|---|---|---|
| Sex, No. (%) | |||
| Male | 67 (94.4) | 54 (96.4) | 0.694 |
| Female | 4 (5.6) | 2 (3.6) | |
| Age, mean ± SD, years | 60.3 ± 9.6 | 55.5 ± 9.0 | 0.005 |
| Tumor Location, No. (%) | |||
| Pyriform sinus | 56 (78.9) | 44 (78.6) | 0.282 |
| Posterior pharyngeal wall | 5 (7.0) | 8 (14.3) | |
| Postcricoid region | 9 (12.7) | 4 (7.1) | |
| Invasion sites, No. (%) | |||
| Esophagus | 12 (16.9) | 7 (12.5) | 0.089 |
| Tongue root | 0 | 3 (5.4) | |
| Thyroid cartilage | 18 (25.4) | 20 (35.7) | |
| Multiple | 37 (52.1) | 25 (44.6) | |
| None | 4 (5.6) | 1 (1.8) | |
| Histological grade, No. (%) | |||
| Low grade | 6 (8.5) | 11 (19.6) | 0.159 |
| Intermediate grade | 46 (64.8) | 34 (60.7) | |
| High grade | 19 (26.8) | 11 (19.6) | |
| T stage, No. (%) | |||
| 1 | 5 (7.0) | 1 (1.8) | 0.071 |
| 2 | 25 (35.2) | 12 (21.4) | |
| 3 | 16 (22.5) | 12 (21.4) | |
| 4 | 25 (35.2) | 31 (55.4) | |
| N stage, No. (%) | |||
| 0 | 8 (11.3) | 1 (1.8) | 0.123 |
| 1 | 15 (21.1) | 17 (30.4) | |
| 2 | 46 (64.8) | 36 (64.3) | |
| 3 | 2 (2.8) | 2 (3.6) | |
| Overall stage, No. (%) | |||
| 3 | 19 (26.8) | 20 (35.7) | 0.594 |
| 4 | 52 (73.2) | 36 (64.3) | |
| LN size (cm), mean ± SD | 1.93 ± 1.39 | 1.81 ± 0.87 | 0.566 |
| NLR (%), mean ± SD | 3.16 ± 1.93 | 3.27 ± 2.15 | 0.786 |
| HGB (g/L) | 140.4 ± 12.8 | 125.4 ± 13.1 | <0.001 |
| PLT (× 109/L) | 244.3 ± 59.1 | 279.0 ± 93.5 | 0.012 |
T, tumor; N, node; LN, Lymph node; NLR, neutrophil lymphocyte ratio; HGB, hemoglobin; PLT, platelet; SD, standard deviation.